| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 835 | 2013 |
| Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ... Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012 | 696 | 2012 |
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ... Journal of clinical oncology 29 (23), 3179-3184, 2011 | 598 | 2011 |
| Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients A Carobbio, J Thiele, F Passamonti, E Rumi, M Ruggeri, F Rodeghiero, ... Blood, The Journal of the American Society of Hematology 117 (22), 5857-5859, 2011 | 537 | 2011 |
| Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status A Carobbio, G Finazzi, V Guerini, O Spinelli, F Delaini, R Marchioli, ... Blood 109 (6), 2310-2313, 2007 | 448 | 2007 |
| Thrombosis in primary myelofibrosis: incidence and risk factors T Barbui, A Carobbio, F Cervantes, AM Vannucchi, P Guglielmelli, ... Blood, The Journal of the American Society of Hematology 115 (4), 778-782, 2010 | 330 | 2010 |
| A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on … F Passamonti, J Thiele, F Girodon, E Rumi, A Carobbio, H Gisslinger, ... Blood, The Journal of the American Society of Hematology 120 (6), 1197-1201, 2012 | 328 | 2012 |
| Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial A Brucato, M Imazio, M Gattorno, G Lazaros, S Maestroni, M Carraro, ... Jama 316 (18), 1906-1912, 2016 | 316 | 2016 |
| Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia T Barbui, AM Vannucchi, V Buxhofer-Ausch, V De Stefano, S Betti, ... Blood 126 (23), 4055, 2015 | 290 | 2015 |
| A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms A Rambaldi, CM Dellacasa, G Finazzi, A Carobbio, ML Ferrari, ... British journal of haematology 150 (4), 446-455, 2010 | 277 | 2010 |
| Leukocytosis and risk stratification assessment in essential thrombocythemia A Carobbio, E Antonioli, P Guglielmelli, AM Vannucchi, F Delaini, ... Journal of Clinical Oncology 26 (16), 2732-2736, 2008 | 248 | 2008 |
| Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts C Capelli, M Domenghini, G Borleri, P Bellavita, R Poma, A Carobbio, ... Bone marrow transplantation 40 (8), 785-791, 2007 | 221 | 2007 |
| Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 T Barbui, A Carobbio, G Finazzi, AM Vannucchi, G Barosi, E Antonioli, ... haematologica 96 (2), 315, 2011 | 205 | 2011 |
| Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, M Ruggeri, ... Leukemia 26 (4), 716-719, 2012 | 202 | 2012 |
| Masked polycythemia vera (mPV): results of an international study T Barbui, J Thiele, H Gisslinger, G Finazzi, A Carobbio, E Rumi, ... American journal of hematology 89 (1), 52-54, 2014 | 199 | 2014 |
| The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F V Guerini, V Barbui, O Spinelli, A Salvi, C Dellacasa, A Carobbio, ... Leukemia 22 (4), 740-747, 2008 | 181 | 2008 |
| Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in … C Tarella, R Passera, M Magni, F Benedetti, A Rossi, A Gueli, C Patti, ... Journal of Clinical Oncology 29 (7), 814-824, 2011 | 178 | 2011 |
| PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics D Massi, D Brusa, B Merelli, M Ciano, V Audrito, S Serra, R Buonincontri, ... Annals of oncology 25 (12), 2433-2442, 2014 | 156 | 2014 |
| In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology T Barbui, A Carobbio, E Rumi, G Finazzi, H Gisslinger, F Rodeghiero, ... Blood, The Journal of the American Society of Hematology 124 (19), 3021-3023, 2014 | 156 | 2014 |
| Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis A Carobbio, A Ferrari, A Masciulli, A Ghirardi, G Barosi, T Barbui Blood advances 3 (11), 1729-1737, 2019 | 151 | 2019 |
